GlassScriptPhysician profile
David B Kimbell
NPI 1427057819
$1,273.58
in general payments reported to CMS, 2019-2025
22 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $104 · 2021: $405 · 2022: $112 · 2023: $124 · 2024: $44.02 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $267.15 | 2019-2020 | |
| Welch Allyn | $225.00 | 2021 | |
| Novo Nordisk INC | $193.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $95.52 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.89 | 2019-2021 | |
| Eisai INC. | $57.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $43.34 | 2020-2025 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $41.47 | 2022 | |
| Pfizer INC. | $40.67 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.69 | 2020 | |
| Sumitomo Pharma America, INC. | $26.23 | 2023 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $25.44 | 2020-2022 | |
| Ge Healthcare | $18.25 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.72 | 2024 | Gvoke Hypopen |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $14.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.02 | 2023 | Spravato |
| Lundbeck LLC | $13.63 | 2024 | Rexulti |
| Allergan, INC. | $12.89 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.61 | 2022 | |
| Astellas Pharma US INC | $11.26 | 2021 | |
| Phathom Pharmaceuticals, INC. | $6.85 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kimbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.